The past year has been a challenging one, but thanks to your generous support and that of other donors, we have been able to continue funding the work of scientists and even expand our research projects during a difficult period of economic…
The 2022 Give to Cure Cancer Year-End Appeal is now underway. It’s your last chance to make this year’s campaign the most successful ever.
We are proud to report...
The year 2022 turns out to be an unprecedented time of new challenges.…
Effective treatments are still lacking for hepatocellular carcinoma or HCC, the most common type of liver cancer and second leading cause of cancer-related fatalities in Asia. Prognosis of patients with the disease has been and remains poor, with a 0.9 ratio of…
I hope this letter finds you safe and well. Over the last several months, the world’s focus and concern has been dominated by the COVID-19 pandemic. However, there is an even greater threat that claims the lives of 9.5 million people each…
Immunotherapy. Angiogenesis. Precision Medicine. Genomic Testing.
Biomarkers. Therapeutic Antibody Engineering. CAR T Cell Therapy.
When the Asian Fund for Cancer Research (AFCR) was founded one and half decades ago, many of these words did not exist or were never used in relation to cancer.
But…